We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





Trivalent Influenza Vaccine Reduces Risk of Severe COVID-19, Especially Among High-Risk Groups, Finds Study

By HospiMedica International staff writers
Posted on 09 Jul 2020
Print article
Illustration
Illustration
A new study of COVID-19 patients has demonstrated that a recent trivalent flu vaccine reduces the odds of severe disease, ventilator support requirement, and death, indicating that such vaccines must be used widely to reduce the risk of severe COVID-19, especially among high-risk groups.

The study examined the outcomes in over 92,000 COVID-19 patients in Brazil, who had and had not been given flu vaccinations recently. The researchers found that the mortality in the non-immunized group rose from about 14% in the under-10 age group to 84% among those aged 90 years and above. However, the mortality was lower in all age groups in the immunized group, with the risk being 17% lower in the 10-19 years age group and 3% less in those aged 90 years and above. The study also looked at the age-influenza vaccine relationship and found that among vaccinated patients, there was a significant reduction by over a third in the odds of dying of COVID-19 at 35%, while the odds of dying of COVID-19 was lower by 18%.

Among patients with a positive RT-PCR-proved COVID-19 diagnosis, the association between lower mortality and flu vaccination remained significant. Those with obesity and lung disorders, as well as renal and kidney disorders had a higher risk of death, while those with asthma faced a lower risk. Additionally, patients who had received flu vaccination had 8% lower odds of requiring intensive care and about 20% fewer odds of needing respiratory support. The patients vaccinated in the current round were found to be protected but not those vaccinated earlier. Patients who had been vaccinated before developing symptoms of COVID-19 showed a 20% reduction in the odds of mortality, while there was a 27% reduction in the odds of death in those who had been vaccinated after the onset of symptoms.

The study demonstrates that while influenza vaccines do not increase the risk of adverse outcomes among COVID-19 patients, they do have a protective effect, possibly through several mechanisms. In their study published on the preprint server medRxiv, the researchers have suggested: “Given the high similarities of SARS-CoV-2 and influenza viruses with respect to viral structure, transmission, and pathogenic mechanisms, it seems plausible that both viruses are detected by similar or identical pattern recognition receptors. Their binding to viral RNA can then trigger suitable inflammatory and antiviral responses.”

The study concludes: “In the absence of a COVID-19 vaccine and without a well-established treatment to avert disease progression, induction of trained immunity exerting beneficial, off-target effects might be a fruitful avenue for improving COVID-19 outcomes. Governments should seriously consider promoting flu vaccination at this time in view of the many benefits since reducing the number of severe COVID-19 cases will help relieve the strain on the healthcare system and allow the sickest patients to receive adequate care.”

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Examination Table
Powerline Backrest Top

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.